VCs rush into osteoporosis drugs after FDA guidance shift — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- VCs are rushing into osteoporosis drug development after the FDA issued new guidance that eases regulatory barriers in a therapeutic area long considered too risky.
- Pharma companies are returning to osteoporosis research alongside the investor rush, reversing a long retreat driven by safety concerns and regulatory hurdles.
Why it matters: Capital is flowing back into osteoporosis R&D after years on the sidelines, with the FDA's regulatory shift as the catalyst. New clinical programs from returning pharma companies promise more treatment options for osteoporosis patients.
Ask SkimNews
